Gary Cavanaugh
Psychiatry · Stockton, CANPI 1619087038
Payments from drug & device makers
Across 308 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$760
- Lundbeck LLC$677
- Sunovion Pharmaceuticals Inc.$673
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$549
- Johnson & Johnson$402
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,697100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $1,113 |
| Otsuka America Pharmaceutical, Inc. | 36 | $760 |
| Lundbeck LLC | 35 | $677 |
| Sunovion Pharmaceuticals Inc. | 39 | $673 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $549 |
| Johnson & Johnson | 18 | $402 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $321 |
| Vanda Pharmaceuticals Inc. | 10 | $296 |
| Almatica Pharma LLC | 6 | $145 |
| Shire North American Group Inc | 9 | $117 |
| Alkermes, Inc. | 5 | $104 |
| Axsome Therapeutics, Inc. | 3 | $88 |
| Avanir Pharmaceuticals, Inc. | 4 | $87 |
| Neurocrine Biosciences, Inc. | 4 | $83 |
| Ironshore Pharmaceuticals Inc. | 3 | $59 |
| Bausch Health US, LLC | 3 | $49 |
| Corium, LLC | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| Sage Therapeutics, LLC | 1 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Neuronetics, Inc. | 1 | $18 |
How this compares
$5,709 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 24 | $1,942 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 22 | $1,414 |
| Duloxetine Hcl | 68 | $1,212 |
| Mirtazapine | 33 | $702 |
| Alprazolam | 99 | $646 |
| Lorazepam | 56 | $506 |
| Quetiapine Fumarate | 22 | $450 |
| Temazepam | 23 | $422 |
| Bupropion Hcl SrBupropion Hcl | 33 | $393 |
| Olanzapine | 21 | $318 |
| Zolpidem Tartrate | 48 | $310 |
| Sertraline Hcl | 23 | $279 |
| Clonazepam | 31 | $236 |
| Trazodone Hcl | 48 | $234 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $145 | $27923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Stockton
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.